2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N7488
    Visnadine 477-32-7 98%
    Visnadine is a natural product that can be isolated from bishop's weed. Visnadine is a vasodilator.
    Visnadine
  • HY-N7576
    Anemarrhenasaponin Ia 221317-02-8 99.94%
    Anemarrhenasaponin Ia is a steroidal saponin that can be isolated from the rhizomes of Anemarrhena asphodeloides Bunge. Anemarrhenasaponin Ia inhibits platelet aggregation. Anemarrhenasaponin Ia induces mild concentration-dependent hemolysis. Anemarrhenasaponin Ia inhibits fMLP- and AA-induced superoxide anion production, while enhancing PMA-induced superoxide anion production. Anemarrhenasaponin Ia can be used in studies related to thrombosis.
    Anemarrhenasaponin Ia
  • HY-N8380
    (-)-Latifolin 10154-42-4 98%
    (-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities.
    (-)-Latifolin
  • HY-N8735
    k-Strophanthoside 33279-57-1 98%
    k-Strophanthoside is a cardiac glycoside compound that can be isolated from the seeds of Strophanthus kombe.
    k-Strophanthoside
  • HY-N9149
    Cryptanoside A 98570-81-1 98%
    Cryptanoside A, a cardiac glycoside epoxide, can be isolated from the stems of Cryptolepis dubia. Cryptanoside A has potent cytotoxicity against cancer cells. Cryptanoside A also inhibits Na+/K+-ATPase activity. Cryptanoside A increases the expression of Akt and the p65 subunit of NF-κB.
    Cryptanoside A
  • HY-N9422
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine 936827-87-1 98%
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group.
    Adenosine 3'-phosphate 5'-phosphosulfate triethylamine
  • HY-N9520
    1-Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone 120693-52-9 98%
    Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is an antagonist of angiotensin II receptor (IC50=48.2 μM). Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9 is a quinolone alkaloid from Evodia rutaecarpa.
    1-Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone
  • HY-P1168
    [Orn8]-Urotensin II (human) 479065-85-5 98%
    [Orn8]-Urotensin II (human), a peptide analog of urotensin II, is a UT receptor agonist. [Orn8]-Urotensin II (human) increases intracellular calcium levels in HEK293.
    [Orn8]-Urotensin II (human)
  • HY-P2072
    GF109 79873-93-1 98%
    GF109 is a potent parenteral inhibitor of angiotensin converting enzyme (ACE). GF109 has antihypertensive effects.
    GF109
  • HY-P3269
    Calciseptine 178805-91-9 98%
    Calciseptine is a natural polypeptide toxin found in the venom of the black mamba snake (Dendroaspis p. polylepis). Calciseptine is a highly effective and selective blocker of the L-type channel of the Cav1.2 subtype, with an IC50 value of 92 nM. Calciseptine has no effect on Cav3.1, Cav2.2, Cav2.1, Cav1.1, voltage-sensitive sodium channels and potassium channels. Calciseptine exhibits negative inotropic and negative relaxant effects on mice, and does not affect heart rate or the action potential of sinoatrial node pacemaker cells. Calciseptine can be used for research on cardiovascular diseases[1].
    Calciseptine
  • HY-P4551
    Hippuryl-His-Leu-OH 31373-65-6 98%
    Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) is a specific substrate for angiotensin-converting enzyme (ACE I) and a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The released His-Leu can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of ACE activity changes in physiological and pathological processes such as renal compensatory hypertrophy.
    Hippuryl-His-Leu-OH
  • HY-P5006
    (d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin 176714-12-8 98%
    (d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin (d(CH2)5[Tyr(Me)2, Dab5]AVP) is a specific antagonist of vasopressin V1a receptor, with a pA2 of 6.71.
    (d(CH2)51,Tyr(Me)2,Dab5,Arg8)-Vasopressin
  • HY-Z3151
    3'-(2-Fluorophenyl) ezetimibe 1798008-25-9 98%
    3'-(2-Fluorophenyl) ezetimibe is an isomer of the cholesterol transport inhibitor Ezetimibe (HY-17376).
    3'-(2-Fluorophenyl) ezetimibe
  • HY-Z6544
    N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride 50295-20-0 98%
    N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride is an impurity in the sodium channel inhibitor Lidocaine (HY-B0185).
    N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride
  • HY-Z8381
    Ramipril diketopiperazine 108731-95-9 98%
    Ramipril diketopiperazine is an impurity in the ACE inhibitor Ramipril (HY-B0279).
    Ramipril diketopiperazine
  • HY-100145
    Prifuroline 70833-07-7 98%
    Prifuroline is an antiarrhythmic agent.
    Prifuroline
  • HY-10064R
    Ticagrelor (Standard) 274693-27-5 98%
    Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
    Ticagrelor (Standard)
  • HY-10111R
    TG100-115 (Standard) 677297-51-7 98%
    TG100-115 (Standard) is the analytical standard of TG100-115 (HY-10111). This product is intended for research and analytical applications. TG100-115 is a selective PI3Kγ/PI3Kδ inhibitor with IC50s of 83 and 235 nM, respectively.
    TG100-115 (Standard)
  • HY-10119R
    Vorapaxar (Standard) 618385-01-6 98%
    Vorapaxar (Standard) is the analytical standard of Vorapaxar. This product is intended for research and analytical applications. Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.
    Vorapaxar (Standard)
  • HY-101431
    Xibenolol hydrochloride 15263-30-6 98%
    Xibenolol hydrochloride (D32 hydrochloride) is an orally active beta-adrenoceptor blocking agent. Xibenolol hydrochloride can be used in the research of tachycardia and hypotension.
    Xibenolol hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity